Literature DB >> 29904878

Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results and changes in catastrophising attitude. Preliminary data.

Licia Grazzi1, Eleonora Grignani2, Emanuela Sansone3, Alberto Raggi2, Matilde Leonardi2, Domenico D'Amico3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29904878     DOI： 10.1007/s10072-018-3387-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  3 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.

Authors:  Sheena K Aurora; Paul Winner; Marshall C Freeman; Egilius L Spierings; Jessica O Heiring; Ronald E DeGryse; Amanda M VanDenburgh; Marissa E Nolan; Catherine C Turkel
Journal:  Headache       Date:  2011-08-29       Impact factor: 5.887

2.  Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety.

Authors:  Guy P Boudreau; Brian M Grosberg; Peter J McAllister; Richard B Lipton; Dawn C Buse
Journal:  Int J Gen Med       Date:  2015-02-18

3.  A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.

Authors:  Andrea Negro; Martina Curto; Luana Lionetto; Paolo Martelletti
Journal:  J Headache Pain       Date:  2016-01-21       Impact factor: 7.277
  3 in total
  1 in total

1.  Clinical Observation of Botulinum Toxin Injection in the Treatment of Focal Dystonia and Muscle Spasm.

Authors:  Zhen Zhang
Journal:  Biomed Res Int       Date:  2022-09-05       Impact factor: 3.246
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.